CME Outfitters Medical Education

39 Episodes
Subscribe

By: CME Outfitters Medical Education

CMEOcast, a clinical podcast presented by CME Outfitters designed to improve clinician performance and optimize patient outcomes. Learn more about CME Outfitters at www.cmeoutfitters.com.

✂️ Clip this podcast
Improving Early Identification and Integrated Management of Cardio-Renal-Metabolic Risk in Family Medicine
Today at 3:00 PM

This CME Outfitters recorded symposium equips family medicine clinicians with practical, workflow-ready strategies to recognize and manage CKM disease as a unified continuum. In this activity, participants will explore the shared pathophysiology linking cardiovascular, kidney, and metabolic disease; sharpen their use of combined eGFR and uACR screening and KDIGO risk stratification; and apply guideline-aligned, patient-centered approaches that include shared decision-making and multidisciplinary coordination to optimize cardiorenal protection across overlapping comorbidities.

Learn More Here


Beyond VEGF: Understanding Blood-Retinal Barrier Biology and Emerging Mechanisms in DME and Neovascular AMD
Last Friday at 9:00 PM

This CME Outfitters recorded symposium will ground learners in the biology of BRB breakdown, weigh the mechanistic rationale behind therapies designed to restore barrier stability, and share practical strategies for recognizing and managing the anti-VEGF incomplete responder, essential context for retina specialists, ophthalmologists, optometrists, and the teams who care for these patients.

Learn More Here


Individualizing HIV Treatment for Diverse Populations
Last Friday at 9:00 PM

In this CMEO Snack, expert faculty will discuss global HIV treatment guidelines and available ART regimens, including standard and long-acting options, with a focus on selecting optimal, evidence-based ART tailored to individual patient needs and preferences. Faculty will also explore simplification and switching of treatments, pre-switch evaluation, identification of heavily treatment-experienced patients and those requiring special considerations, counseling on dose frequency, and the importance of culturally responsive, patient-centered communication across diverse global settings.

Learn More Here


Integrating Clinical Trial Evidence into Global HIV Practice
Last Friday at 9:00 PM

In this CMEO Snack, expert faculty will discuss recent clinical trial and real-world data on the efficacy and safety of novel and emerging HIV therapies, including LAIs, and how treatment guidelines have evolved across global frameworks. Faculty will also examine how emerging evidence may shape the landscape of future clinical practice in different regions.

Learn More Here


Global Guidelines and Strategies for HIV Screening and Diagnosis
Last Friday at 9:00 PM

In this CMEO Snack, expert faculty will discuss the role of HIV testing in connecting individuals to the care continuum, with a focus on global testing guidelines. Faculty will also explore strategies for increasing HIV testing uptake across the socioeconomic spectrum by reviewing effective communication approaches to address stigma, bias, and access/resource barriers; comparing testing practices and guideline recommendations by region; and outlining rapid-start and same-day ART initiation workflows following diagnosis.

Learn More Here


Implementation and Access in Global HIV Care
Last Friday at 9:00 PM

In this CMEO Snack, faculty will discuss strategies for addressing these ongoing gaps in HIV care, including integration of optimized workflows that entail patient counseling, shared decision-making, interprofessional collaboration, and individualized treatment to achieve real-world practice change for all populations.

Learn More Here


From Biomarkers to Bedside: Translating IIM Classification into Targeted Treatment Strategies
11/09/2026

In this case-based CME Outfitters recorded webcast, expert faculty will guide learners through real-world diagnostic and treatment decision points that translate biomarker-informed IIM classification into clinical practice, linking subtype recognition to further diagnostic evaluation, targeted comorbidity assessment, multidisciplinary care, and current and emerging steroid-sparing treatment strategies. Patient perspectives on function, treatment burden, quality of life, and personal goals will be integrated into these decisions, while investigational FcRn inhibition is considered within a fair and balanced therapeutic landscape.

Learn More Here


A CaseWise™ Webcast – CIDP in Focus: Advancing Precision Across the Patient Journey from Early Recognition to Downstream Management
11/09/2026

In this recorded CaseWise™ webcast from CME Outfitters, expert faculty bring real-world clinical decision-making to life. Through dynamic patient cases, learners will explore key clinical challenges to help sharpen diagnostic confidence, individualize treatment, and help patients achieve better long-term outcomes.

Learn More Here


Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes
11/09/2026

This fast-paced and highly interactive recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how the immunometabolic impact of visceral and mesenteric adiposity on disease activity, treatment response, and surgical risk translates into practice, what doesn’t translate, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply validated adiposity assessment methods, confidently integrate GLP-1 RAs into...


CME Snack FGF21 Frontier in Clinically Significant MASH
10/22/2026

In this CME Outfitters Snack, expert faculty will assist learners to explore the role of FGF21 across metabolic and fibrotic pathways, interpret emerging clinical evidence for FGF21 analogues in clinically significant MASH, and examine the scientific rationale for targeting the FGF21 pathway in patients with compensated cirrhosis due to MASH.

Learn More Here


Webcast A CaseWise™ Webcast – Precision in Practice: Individualizing FcRn Inhibitor Use in Generalized Myasthenia Gravis
10/22/2026

In this CME Outfitters recorded webcast, expert faculty will use real-world cases and perspectives from across the gMG care team to strengthen candidate recognition, evidence-based treatment selection, longitudinal monitoring, and shared decision-making. Education will clarify team roles and support individualized care, addressing symptom fluctuation, safety, administration preferences, treatment burden, and outcomes most meaningful to patients, including minimal symptom expression and preserved daily function.

Learn More Here


Riding the Waves of Obesity Science – Reaching the Shoreline: Emerging Amylin-Based Therapies and Trial Signals
10/01/2026

As the fourth and final segment, this conversation brings the series full circle. After framing obesity’s heterogeneity, exploring amylin biology, and considering phenotype-guided care, it turns to the closing question: as these therapies arrive, how do we evaluate them — and whom might they help? A forward-looking, evidence-grounded finish for clinicians preparing for what comes next. All data discussed are investigational and presented as such.

Learn More Here


Riding the Waves of Obesity Science – The Phenotype Breakers: Heterogeneity, Signals, and Who Might Benefit from Which Biology
09/18/2026

In this conversation, Andres Acosta, MD, PhD, joins series chair Robert F. Kushner, MD, to explore obesity phenotypes as a framework for individualizing care. Dr. Acosta examines how differences in appetite, satiety, energy expenditure, and eating behavior may help explain the wide variation in treatment response — and offers a candid appraisal of how far the science has come and how far it still has to go, since validated predictors of drug response are not yet established.

As the third of four conversations, this segment turns the series’ theme of heterogeneity into a practical lens. After framing why mult...


Extraintestinal Manifestations in IBD — Screening, Referral Triggers, and Multidisciplinary Care Pathways
09/11/2026

In the third activity of this CMEO podcast series, expert faculty will assist learners to recognize common and clinically significant extraintestinal manifestations associated with IBD, incorporate practical screening approaches into routine clinical workflows, and implement multidisciplinary care strategies for patients with systemic disease involvement.

Learn More Here


Riding the Waves of Obesity Science – Amylin at a Glance: A Mechanistic Map of a Systems Satiety Signal
08/28/2026

In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a s...


Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current
08/28/2026

In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promis...


Case Closed? Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects
08/25/2026

Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and frustrating atop the disease burden itself. Overlapping symptoms with conditions such as depression, anxiety, and cardiovascular disease often obscure the true cause, while distinguishing IH itself from narcoleptic sleep disorders can be equally complex. As a rare condition, IH can leave patients feeling isolated and misunderstood while enduring an unpredictable constellation of symptoms. By sharpening diagnostic precision and fostering...


Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team
08/20/2026

The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.

In the first activity of this EfficientCME webcast series, two leading breast oncologists and a partnering pathologist examine the evolving understanding of...


Fibrosis in IBD — Pathogenesis, Risk Stratification, and Objective Monitoring
08/19/2026

Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing patients at risk for fibrotic progression and inconsistently apply objective monitoring and management strategies until complications have already developed. In addition, evolving insights into the biologic mechanisms driving chronic tissue remodeling and emerging therapeutic approaches targeting these pathways have not yet been fully integrated into routine clinical practice. This podcast, designed for gastroenterologists, GI fellows, physician associates, nurse practitioners...


Webcast: CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes
08/14/2026

In this CME Outfitters Engage the Experts recorded session, the community-based expert faculty from the Project ECHO® series will provide a comprehensive summary of key insights from the five-session CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes – A Project ECHO® Initiative series. Topics will include the clinical heterogeneity and pathophysiology of CIDP and the significance of IgG autoantibodies in its development, guideline-recommended diagnostic criteria to identify patients with CIDP, current and emerging treatment options including limitations of standard therapies and appropriate integration of novel agents into practice, and how to use collaborative care strategies to enhance long-term outcomes and qual...


Cleared for Takeoff: An All-Hands-on Deck Approach to Building Confidence and Competence in S1P Receptor Modulator Initiation for Ulcerative Colitis
08/14/2026

For people living with ulcerative colitis (UC), cycles of remission and relapse can disrupt daily life and complicate long-term management. Sphingosine-1-phosphate receptor modulators (S1Prms) are a new class of targeted oral therapies with the potential to reduce colonic inflammation and improve outcomes. Initiating them follows a clear, well-defined pathway: a focused set of baseline assessments supports safe, confident use and helps teams match the right patients to therapy. With practical, evidence-based education, clinicians and multidisciplinary care teams can bring S1Prms into routine practice with confidence.

This CME Outfitters recorded webcast makes that pathway clear...


Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current
08/13/2026

In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promis...


Beyond Symptoms — The Hidden Burden of IBD and the Future of Disease Modification
08/07/2026

Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often focus primarily on luminal inflammation, with limited integration of fibrosis, extraintestinal manifestations (EIMs), and cumulative inflammatory burden into long-term treatment planning and disease modification strategies. As emerging scientific concepts and therapeutic approaches increasingly aim to alter the trajectory of IBD progression, clinicians such as gastroenterologists, GI fellows, physician associates, nurse practitioners, nurses, nurses, and pharmacists require a deeper understanding...


Rethinking Suppression: GnRH Antagonists and Contemporary Endometriosis Management
07/17/2026

Endometriosis is a chronic inflammatory condition that remains underrecognized and undertreated, leaving many individuals of reproductive age with daily pain and disruption. Patients often face preference‑sensitive decisions about pain management, contraception, and fertility without clear guidance, frequently after years‑long diagnostic delays. Although gonadotropin‑releasing hormone (GnRH) antagonists and other contemporary therapies have expanded options for endometriosis‑associated pain, many clinicians remain anchored to NSAIDs and combined hormonal contraceptives, leading to suboptimal selection and sequencing of non‑surgical treatments. Community clinicians, particularly in underserved settings, face additional challenges due to limited resources and specialty support. By equipping clinicians with cutti...


Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Inhibitors
07/14/2026

Generalized myasthenia gravis (gMG) is a chronic neuromuscular disorder that results from destruction of the neuromuscular junction by pathogenic autoantibodies, partially through the actions of the neonatal Fc receptor (FcRn). Traditional therapies only partially alleviate the heavy disease burden and episodic exacerbations characteristic of gMG. In recent years, FcRn antagonists have shown great promise across broad gMG populations. Clinicians in collaboration with a multidisciplinary care team must understand the potential benefits of FcRn agonists and update best practices to care for patients with gMG.

In this CME Outfitters recorded webcast, expert faculty will discuss the role of...


Risk Stratification in Hospitalized SARS-CoV-2 Patients
07/10/2026

Comprehensive patient assessment and accurate risk stratification are cornerstones of effective inpatient management of SARS-CoV-2. However, the absence of a clear consensus on how to categorize patients by risk—and the limited availability of validated, reliable scoring systems—continues to challenge clinical decision-making. With therapeutic choices often hinging on disease severity and progression risk, healthcare professionals face uncertainty in selecting the most appropriate tools to inform treatment. This educational initiative will offer guidance on navigating the strengths and limitations of existing risk prediction models as well as their application across varied clinical scenarios to enhance individualized patient care and outc...


Unraveling the Complexities of cUTI Care: Modernizing cUTI Care with the 2025 IDSA and EAU Updates
07/10/2026

Complicated urinary tract infections (cUTIs) represent an important and growing challenge in clinical practice, affecting individual patients’ health and quality of life while exerting a substantial burden on the healthcare system. Despite being common, these infections are underrecognized. The July 2025 Infectious Diseases Society of America (IDSA) and concurrent EAU guidelines have redefined the classification of UTIs, emphasizing severity, resistance risk factors, and patient-specific considerations, allowing for more precise diagnosis and treatment selection. It is, therefore, imperative for clinicians and care systems to update their approach to diagnosing, treating, and transitioning care for patients with cUTI.

In this CM...


Improving Quality of Life and Care in Lennox-Gastaut Syndrome: Best Practices for Collaborative, Family- and Patient-Centered Management
07/10/2026

Lennox-Gastaut syndrome (LGS) affects every aspect of patients’ and caregivers’ lives, often far beyond seizures alone. Families face a fragmented system, where pediatric and adult care are poorly aligned, social services are hard to navigate, and long-term planning is unsupported. Younger patients with LGS are frequently misunderstood in emergency and school settings, while older patients may experience isolation and lack of access to appropriate adult services. These gaps contribute to caregiver fatigue, emotional distress, and a loss of confidence in support systems. Clinicians and multidisciplinary care teams require best-in-class education to address these gaps, meet the early and lifelong need...


Addressing Unmet Needs in Retinal Disease: Pairing Therapeutic Advances with Personalized Care
07/10/2026

Retinal disease includes a wide array of conditions affecting the retina that, if not detected and treated early, can significantly impair quality of life, independence, and mobility while increasing the risk of accidental injury. These conditions also impose a substantial socioeconomic burden through health care costs, lost productivity, and disability. Persistent gaps in care and treatment contribute to ongoing disease burden, underscoring the need for continued advances in therapies, guidelines, and clinician education to improve outcomes and reduce treatment burden for patients with retinal disease.

In this CME Outfitters recorded webcast, expert faculty will discuss guideline-recommended approaches...


Breaking Barriers – Implementing Status-Neutral HIV Screening and Prevention for All
07/10/2026

Despite significant strides in HIV prevention, global incidence rates remain high, especially among underserved populations, due in part to persistent barriers in routine screening and access to pre-exposure prophylaxis (PrEP). Many healthcare professionals across the globe, including HIV and infectious disease specialists, primary care clinicians, and pharmacists, lack adequate training on implementing status-neutral screening strategies and integrating newer PrEP modalities, such as long-acting injectables, into practice. Cultural stigma, low health literacy, and system-level workflow challenges further hinder global prevention efforts and widen care disparities. Education is needed to equip clinicians worldwide with the tools, knowledge, and confidence to adopt...


A CaseWise™ Initiative – Mission Possible: Matching Treatment Goals of Patients and Providers in IBD in Clinical Practice
07/10/2026

Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While gastroenterologists and other members of the care team are increasingly aware of new efficacy and safety data, many report uncertainty in selecting, sequencing, and communicating these treatment choices in ways that align with patient preferences, quality-of-life priorities, and long-term disease control.

This fast-paced recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Thro...


Staying Current – Navigating the Latest Advances in PrEP Options
07/10/2026

As HIV prevention strategies continue to evolve, healthcare professionals across the globe face persistent knowledge gaps in evaluating and integrating the latest pre-exposure prophylaxis (PrEP) options, including long-acting injectable (LAI) agents. Many clinicians worldwide remain unfamiliar with the mechanisms of action (MOA), tolerability and safety profiles, and administration considerations associated with newer PrEP formulations, limiting their ability to tailor prevention strategies to specific patient needs. This lack of up-to-date training contributes to underutilization of PrEP, missed prevention opportunities, and ongoing disparities in care delivery. Education is needed for HIV/infectious disease (ID) specialists, primary care providers, pharmacists, and other...


Expanding Access – Optimizing Use of Long-Acting Injectable PrEP
07/10/2026

Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) represents a major advancement in HIV prevention, offering new opportunities to support adherence and reduce transmission, yet its optimal use remains underrealized across global healthcare settings. Many HIV/infectious disease specialists, primary care clinicians, and pharmacists worldwide lack clarity on patient selection criteria, initiation and transition strategies, and long-term monitoring requirements for LAI PrEP. These gaps, coupled with limited training and implementation barriers such as workflow challenges and stigma, restrict access for populations that could benefit most. Targeted education is needed to equip providers across the globe with the practical knowledge and confidence...


Transforming MS Care: Advanced Strategies in Multiple Sclerosis Management
07/10/2026

Multiple sclerosis (MS) is a chronic, immune-mediated disease in which early, individualized disease-modifying therapy (DMT) can reduce disease activity, delay disability progression, and preserve quality of life. As therapeutic options expand—particularly multiple anti-CD20 therapies with different dosing schedules, administration routes, and safety considerations—clinicians must accurately interpret trial and real-world data, weigh risk–benefit trade-offs, and align recommendations with patient goals. Inconsistent application of evidence-based MS management guidelines and variability in monitoring practices can contribute to suboptimal therapeutic outcomes, especially in older and pediatric patients, whose physiological and social considerations may affect tolerability, adherence, and long-term disease control.

I...


Breaking Barriers to Better Hearts: Optimizing LDL-C Management for Cardiovascular Risk Reduction
07/10/2026

Despite advances in the prevention and management of atherosclerotic cardiovascular disease (ASCVD), gaps remain in real-world risk assessment and lipid-lowering treatment, particularly among intermediate- and high-risk patients. Inconsistent use of risk assessment tools, variable evaluation of risk-enhancing factors, and suboptimal initiation or intensification of lipid-lowering therapies contribute to therapeutic inertia and prevent many patients from achieving recommended low-density lipoprotein cholesterol (LDL-C) targets. These challenges are compounded by evolving guidelines, increasing treatment complexity, and the expanding availability of non-statin therapies. Targeted education is essential to improve clinicians’ ability to apply current guidelines, prioritize LDL-C goal attainment, and implement evidence-based strategies—incl...


Breaking Barriers to Better Hearts: Optimizing LDL-C Management for Cardiovascular Risk Reduction
07/06/2026

In this CME Outfitters recorded webcast, expert faculty will review current ASCVD risk assessment guidelines, highlight the importance of achieving recommended LDL-C targets in intermediate- and high-risk patients, and discuss practical strategies to optimize therapeutic decision-making in clinical practice.

Learn More Here


Partnering for Success – Patient Engagement and PrEP Adherence Strategies
07/06/2026

Across diverse global settings, patient engagement and sustained adherence remain major challenges in HIV prevention, particularly with pre-exposure prophylaxis (PrEP). Barriers such as insufficient provider training in communication strategies, in addition to broader issues such as stigma, limited health literacy, and cultural norms, often undermine initiation and long-term use of PrEP. Healthcare professionals, including HIV/infectious disease (ID) specialists, primary care providers, nurses, and pharmacists, need practical education on how to build trust, tailor engagement, and co-create adherence plans that reflect patients’ lived experiences and preferences. Empowering clinicians with effective, culturally sensitive strategies for patient-centered care is essential to cl...


Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
06/24/2026

In this CE Concepts recorded webcast, expert faculty will review recent developments in the management of advanced or recurrent EC, with a focus on applying emerging clinical evidence, integrating biomarker-driven therapies, and addressing treatment-related toxicities. This program will further explore strategies to enhance interprofessional collaboration, support equitable access to molecular testing and novel therapies, and strengthen patient-centered education to optimize care delivery.

View the activity here


A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
06/24/2026

In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.

View the activity here